At the time of writing, Axsome Therapeutics Inc [AXSM] stock is trading at $80.66, down -0.25%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AXSM shares have gain 6.78% over the last week, with a monthly amount glided 0.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 19, March 2024, Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder. In a post published today on Yahoo Finance, Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder (MDD).
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on March 19, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $108. Previously, UBS started tracking the stock with Buy rating on February 06, 2024, and set its price target to $111. On January 25, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $126 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $125 on December 13, 2023. BofA Securities upgraded its rating to a Neutral and raised its price target to $81 on August 08, 2023. Piper Sandler started tracking with a Neutral rating for this stock on January 05, 2023, and assigned it a price target of $75. In a note dated November 01, 2022, Loop Capital initiated an Buy rating and provided a target price of $95 on this stock.
For the past year, the stock price of Axsome Therapeutics Inc fluctuated between $55.02 and $98.40. Currently, Wall Street analysts expect the stock to reach $81 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $80.66 at the most recent close of the market. An investor can expect a potential return of 0.42% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
According to Axsome Therapeutics Inc [NASDAQ:AXSM], the company’s sales were 270.60M for trailing twelve months, which represents an 193.50% jump. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.88%, and Net Profit Margin reading is -0.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -1.12 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 79.62 points at the first support level, and at 78.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 81.85, and for the 2nd resistance point, it is at 83.04.
Axsome Therapeutics Inc [AXSM] reported earnings per share of -$2.08 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.17/share, meaning a difference of $-0.91 and a surprise factor of -77.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.32 per share as compared to estimates of -$1.2 per share, a difference of $-0.12 representing a surprise of -10.00%.
Ratios To Look Out For
It is important to note that Axsome Therapeutics Inc [NASDAQ:AXSM] has a current ratio of 3.63. Further, the Quick Ratio stands at 3.52, while the Cash Ratio is 2.78. Considering the valuation of this stock, the price to sales ratio is 14.12, the price to book ratio is 20.00.
Transactions by insiders
Recent insider trading involved JEFFS ROGER, Director, that happened on Mar 15 ’24 when 2347.0 shares were sold. Director, JEFFS ROGER completed a deal on Mar 14 ’24 to sell 29976.0 shares. Meanwhile, Director Coleman Mark sold 18572.0 shares on Sep 15 ’23.
